CN Patent

CN104363896A — 恩替卡韦的药物组合物及制造方法

Assigned to Pharmascience Inc · Expires 2015-02-18 · 11y expired

What this patent protects

本发明涉及用于治疗乙型肝炎病毒感染的无粘结剂药物组合物,其包含至少一种基于鸟嘌呤的抗病毒活性药物成分。更特别的是,本发明涉及包含以下的口服药物组合物:包含治疗有效量的恩替卡韦和至少一种颗粒内药学上可接受的赋形剂的无粘结剂颗粒;至少一种颗粒外药物赋形剂及任选的防潮包衣。还公开了制造无粘结剂药物组合物的方法。

USPTO Abstract

本发明涉及用于治疗乙型肝炎病毒感染的无粘结剂药物组合物,其包含至少一种基于鸟嘌呤的抗病毒活性药物成分。更特别的是,本发明涉及包含以下的口服药物组合物:包含治疗有效量的恩替卡韦和至少一种颗粒内药学上可接受的赋形剂的无粘结剂颗粒;至少一种颗粒外药物赋形剂及任选的防潮包衣。还公开了制造无粘结剂药物组合物的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN104363896A
Jurisdiction
CN
Classification
Expires
2015-02-18
Drug substance claim
No
Drug product claim
No
Assignee
Pharmascience Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.